Nahata M C
Drug Intell Clin Pharm. 1987 May;21(5):399-405. doi: 10.1177/106002808702100501.
Remarkable progress has been made in antiviral chemotherapy. Six approved antiviral drugs are now available for the treatment of various viral infections. Trifluridine, idoxuridine and vidarabine are all effective in patients with herpes keratitis; trifluridine is preferred due to its low toxicity. Acyclovir is the drug of choice in patients with infections due to herpes simplex viruses, including genital herpes, herpes encephalitis, and neonatal herpes, and infections due to varicella-zoster virus. Amantadine is the only drug currently available for prophylaxis and treatment of influenza A, but an investigational drug, rimantadine, appears to be equally effective and less toxic than amantadine. Ribavirin is the most recently approved antiviral agent for the treatment of respiratory syncytial virus infections. Numerous antiviral drugs are being studied in patients with acquired immunodeficiency syndrome. Although currently available drugs have improved our ability to manage a variety of viral illnesses, much needs to be learned about specific dosage guidelines based on the studies of pharmacokinetics, pharmacodynamics, potential adverse effects and viral resistance, and the role of combination therapy to optimize therapy.
抗病毒化疗已取得显著进展。目前有六种获批的抗病毒药物可用于治疗各种病毒感染。曲氟尿苷、碘苷和阿糖腺苷对疱疹性角膜炎患者均有效;由于毒性较低,曲氟尿苷更受青睐。阿昔洛韦是治疗由单纯疱疹病毒引起的感染(包括生殖器疱疹、疱疹性脑炎和新生儿疱疹)以及由水痘-带状疱疹病毒引起的感染的首选药物。金刚烷胺是目前唯一可用于预防和治疗甲型流感的药物,但一种研究性药物金刚乙胺似乎同样有效且毒性比金刚烷胺小。利巴韦林是最近获批用于治疗呼吸道合胞病毒感染的抗病毒药物。目前正在对获得性免疫缺陷综合征患者进行多种抗病毒药物的研究。尽管现有药物提高了我们治疗各种病毒性疾病的能力,但基于药代动力学、药效学、潜在不良反应和病毒耐药性的研究以及联合治疗在优化治疗中的作用,仍有许多关于具体剂量指南的知识需要学习。